Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 176c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q3 EPS of $1.02, $1.76 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $43.74 million versus the consensus estimate of $9.6 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print